Bekjemper kreft med gentilpasset behandling

Gentilpasset behandling har siden begynnelsen av 2000-tallet blitt beskrevet som et av de nye, viktige våpnene som kan bekjempe kreft.

Hør forsker Hege G. Russnes og professor Anne Hansen Ree, her fra Cancer Crosllinks i januar i år, fortelle om deres forskningsprosjekt MetAction, og hvordan de tar i bruk gentilpasset behandling for å gi et behandlingstilbud til en pasientgruppe som har manglet det tidligere. Nå avsluttes prosjektet og du kan høre her hvorfor forskerne synes det er både feil og trist.

Forskningsprosjektet, som varte fra 2014 til 2017, ble ledet av Ree, kreftforsker og professor Gunhild Mari Mælandsmo, molekylærpatolog og lege Hege Russnes ved Oslo universitetssykehus, samt kreftkirurg og lege Kjersti Flatmark.

I forrige uke fikk de også forsiden på VG. Og det med god grunn: Ved bruk av genterapi og tverrfaglig kompetanse gir de hjelp til nye pasientergrupper og løfter norsk kompetanse innen gentilpasset behandling.

Les saken i VG her.

10th Cancer Crosslinks: Precision Treatment Reviewed

For the tenth time the cancer experts gathered to share knowledge and ideas at Oslo Cancer Cluster Innovation Park. Cancer Crosslinks 2018 presented a diverse program covering themes from immuno-oncology to cachexia, to big data.

 

Cancer research is changing rapidly. Immunotherapy and precision medicine has revolutionized cancer treatment. This year’s Cancer Crosslinks took a closer look at developments over the last decade, and highlighted “Precision Treatment: Exploiting Recent Advances – Fast and Furious?”.

Weber Gazed into the Crystal Ball
The leading immunotherapy expert professor Jeffrey S. Weber visited Cancer Crosslinks for a second time. Weber has worked with immunotherapy for 30 years.  He provided an overview on recent advances. He shared new data showing that the combination of a certain vaccine and a type of immunotherapy called Checkpoint inhibitors, are especially effective against cancer. He also gazed into the crystal ball and made predictions on the future of cancer treatment. Weber is optimistic and thinks there are several promising combinations of precision treatments on the horizon.  He believes we can hope for a survival rate of 70-80 percent for people with certain cancers.

A Fiber Diet is Recommendable
Professor Laure Bindels from Belgium explored the theme of Microbiome, Cancer and Cachexia. Diet can be an important tool to fight cancer and cancer symptoms. Her research on mice indicates that changing to a fiber-rich diet can prevent undernourishment and increase the survival rate for cancer patients.

Hege Russnes and Anne Hansen Ree introduced us to the MetAction project where they conduct extended personal diagnostic testing to give cancer patients better and more effective treatment.

From the USA, we were introduced to precision treatment of gynecological cancer from Douglas A. Levine.  He was followed by Professor Andreas Engert, who raised the hot topic of establishing joint European guidelines for treatment across Europe for hematological cancer.

A Big Maybe to Big Data
The last speakers of the day where Assistant Professor Marcela Maus from Harvard Medical School, and Elisabeth Wik and Marc Vaudel from the University of Bergen. Professor Maus explained the use of CAR T- cells in cancer treatment. CAR-T Cells are T-cells with modified receptors to make them more effective against certain diseases, in this case cancer.

Elisabeth Wik and Marc Vaudel, with backgrounds from cancer research and computer science, discussed the use of big data in cancer research and treatment. Will big data revolutionize cancer treatment? The answer is maybe. We don’t know yet, it has potential.  We need to continue exploration, research, and collaboration to find out.

Download the Presentations
For those of you who missed the event or would like to revisit:

You may watch most of the presentations here.

You can download presentations from the meeting here:

Opening and Welcome with Jutta Heix from Oslo Cancer Cluster and Anne Kjersti Fahlvik, Executive Director Innovation, The Norwegian Research Council.

Jeffrey S. Weber. Opening Keynote: Cancer Immunotherapy – The Journey So Far and Where We Are Heading.
Jeffrey S. Weber, Professor, Deputy Director and Co-Director, Melanoma Program, Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, USA.

Laure Bindels. International Keynote: The Microbiome, Cancer and Cachexia.
Laure Bindels, Louvain Drug Research Institute, Université catholique de Louvain, Belgium.

Hege G. Russnes and Anne Hansen ReeFrom Feasibility to Utility in Precision Medicine – Experiences from the first Norwegian Study of NGS-Based Therapy Decisions in Advanced Cancer.
Hege G. Russnes, Senior Consultant and Researcher, Oslo University Hospital, Norwegian Radium Hospital, Norway
Anne Hansen Ree, Professor, Akershus University Hospital, University of Oslo, Norway

Douglas A. Levine. International Keynote: Precision Medicine for Gynecologic Cancers – Opportunities and Obstacles.
Douglas A. Levine, Professor, Director of Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center & Head, Gynecology Research Laboratory, NYU Langone Medical Center, New York, USA.

Andreas Engert. International Keynote: Roadmap for European Hematology Research and Hodgkin Lymphoma: (Immuno)therapy, Late Effects and the Way Forward.
Andreas Engert, Professor for Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Germany.

Marcela V. Maus. International Keynote: The Next Generation of Engineered T-cells for Immunotherapy of Hematological and Solid Tumors.
Marcela V. Maus, Assistant Professor, Harvard Medical School & Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital, Boston, USA.

Marc Vaudel  and Elisabeth Wik: Making Sense of Big Data for Oncology Patients – Vision and Reality
Marc Vaudel, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital and KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Norway
Elisabeth Wik, Centre for Cancer Biomarkers, University of Bergen and Department of Pathology, Haukeland University Hospital, Norway

Follow the 10th Cancer Crosslinks: Stream and Program

Thursday January the 18th it’s time for the 10th Cancer Crosslinks here at Oslo Cancer Cluster Innovation Park. Hospital personnel, researchers and everybody interested get together for an update on – and to discuss – the latest within cancer research.

 

This year’s conference will focus on Precision Treatment in cancer research with the headline: Exploiting Recent Advances – Fast and Furious?

Check out the program here.

Follow the stream
Registration for the event is now closed, but the whole event will be streamed and broadcasted here at the website. Just follow this link and you can follow the event live:

Follow the stream here.

Targovax Releases Positive Clinical Results

Targovax has received very positive results regarding the survival rate of patients with pancreatic cancer.

Immune-oncology aims to help the body’s own immune system fight cancer and the ambition is to address the unmet need for long-term survival for patients with advanced cancers.

13 of 13
The company specializes in immune-oncology and is a member of Oslo Cancer Cluster. It recently released information revealing that 13 of 13 test subjects where alive after one year of treatment in a stage two clinical trial study. In addition, an active immune response–meaning the immune system was triggered to attack the cancer–was observed in as much as 11 of 13 patients.

No allergic reactions
These results came after the number of test subjects were reduced from 19 to 13 to see if allergic reactions stalled with reduced dosages of the TG01; Targovax’s lead RAS immunotherapy product. And luckily, no serious allergic reactions were observed,

Magnus  Jäderberg MD, Chief Medical Officer of Targovax, said:

– We are delighted that we maintain a strong immune response and one-year survival rate with the reduced dosing  regimen, essentially  equivalent  to  and  consistent with the previously  reported data  from the  main cohort.

These new results are so positive that stock market analysts DnB Markeds predict a serious stock market rise for Targovax.

 

About Targovax

Arming the patient’s immune system to fight cancer

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

In July, 2016 the Company listed its shares on Oslo Axess.

Read more

 

Podcast on cancer research and development

Oslo Cancer Cluster member Radium Hospital Research Foundation, Radforsk, has launched their own podcast. The podcast is named Radium, and is about cancer research and development of new cancer treatments, as well as updates on Radforsk´s portfolio companies.

Radium has so far made nine episodes, and the ambition of Jónas Einarsson, CEO Radforsk and Elisabeth Kirkeng Andersen, communication manager in Radforsk, is to make one new episode a week. The podcasts are in Norwegian, if they do not interview people from abroad, as they did in the Cancer Crosslinks special.

Einarsson and Andersen is usually joined by guests in the studio, and so far they have had guests from Oslo Cancer Cluster members; PCI Biotech, Ultimovacs, Targovax, Vaccibody, Oncoinvent, as well as Roy Larsen and Øyvind Bruland, talking about Algeta, Nordic Nanovector and Oncoinvent.

Upcoming epiosodes will include guests such as Professor Håvard Danielsen from Institute for Cancer Genetics and Informatics, Anne Lise Ryel, General Secretary in the Norwegian Cancer Society and CEO, Kjetil Hestdal in Photocure.

Here you may find all podcast episodes launched so far.

PERMIDES project going forward with project manager hired

PERMIDES_Gupta_web

Oslo Cancer Cluster and NCE Smart Energy Markets together with four European clusters in medicine and IT managed to land a prestigious Horizon 2020 EU project this spring. The official kick-off for the project is September 7th to 8th in Karlsrue and project manager Gupta Udatha is hired to work in both Oslo and Halden to implement the project from Norwegian side.

 

Project manager Gupta Udatha He works at both the Norwegian Centres of Expertise located in Eastern Norway, i.e. Oslo Cancer Cluster and Smart Innovation Østfold. The PERMIDES project aims at establishing fruitful collaborations between the bio-pharmaceutical and IT sectors in the European region to advance the field of personalised medicine through the development of novel digital solutions with cancer as the model disease.

– Gupta has an amazing background from bioinformatics and big data analytics of biopharmaceutical data. We are confident he is going to drive this project forward in a satisfactory way, says Ketil Widerberg, CEO Oslo Cancer Cluster and Dieter Hirdes, F & I Coordinator Smart Innovation Østfold company as a leader NCE Smart Cluster in a joint comment.

The PERMIDES project will start 1 September and with a kick-off meeting in Karlsruhe 7th to 8th September.

 

 

View presentations and videos from Cancer Crosslinks

Cancer Crosslinks 2016 featured cutting-edge presentations from leading American and Norwegian clinicians and researchers within the field of cancer immunotherapy. You may look at their presentations again or for the first time via following the links below.  You may also watch videos of some of the presentations.

 

Picture above: The three Cancer Crosslinks 2016 keynote speakers.  From left: Professor Renier Brentjens, Dr. Stefanie Spranger and Professor Gordon Freeman.
Photo: U-Casters.

 

Videos:

International keynote presentations:

National presentations:

Presentations are published by courtesy of the lecturers.

Cancer Crosslinks 2016 will be streamed

Cancer Crosslinks 2016 features a really interesting program. For those of you that may not take part of the actual conference in the Oslo Cancer Cluster Innovation Park, you may watch the whole program at your computer as we will live stream from 9:00 – 16:30.

Over 240 people from all over Norway have signed up for this years Cancer Crosslinks. The program focuses on immuno-oncology and features strong international thought leaders as presenters. Cancer Crosslinks is hosted by Oslo Cancer Cluster and sponsored by BMS and Janssen.

 

 

 

Cancer Crosslinks 2016 features thought leaders in immuno-oncology

Cancer Crosslinks 2016 on January 14 offers you an exciting program with international keynote speakers who made and make major contributions to advance immunotherapies against cancer. Already more than 120 delegates have signed up, but we have room for many more in the Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park. The conference is sponsored by BMS and Janssen.

 

 

The main theme for Cancer Crosslinks 2016 is: «The transversal impact of new treatments in Oncology and Hematology: tumor microenvironment, novel concepts, combinations and study design».

 

Some program highlights:

  • Professor Gordon Freeman, Dana-Farber Cancer Institute and Harvard Medical School, is one of the key persons behind today’s PD-1/ PD-L1 inhibitors. He will share his perspectives on PD-1 cancer immunotherapy. His talk will be complemented by case studies from Norway illustrating the broad impact of immune checkpoint inhibitors for a variety of cancers
  • Professor  Renier Brentjens, Memorial Sloan-Kettering Cancer Center, will shift the focus to hematological cancers and discuss the advancement of recombinant T-cell technologies including CAR-T-cell approaches for different indications. Norwegian experts will complement his talk with updates on novel immuno-oncology approaches being developed at UiO and OUS
  • Stefani Spranger from Professor Tom Gajewski’s lab, University of Chicago will provide the latest insights into the role of T-cell inflammed versus non-inflammed tumor microenvironment for immunotherapy
  • Last, but not least: a Norwegian patient will share his perspectives on the importance of novel cancer therapies

 

Travel expences
Participants working at hospitals and/or academic reserach centres whom have no sources for funding the participation will get flight or train ticket covered. How ever we do not cover local transportation to / from the airport. Flight or train tickets may be ordered by connecting to travel agency Berg-Hansen on e-mail:  bestilling@berg-hansen.no or phone  08050 between 08.00-17.00. The reference code is «OCC».

View videos from Cancer Crosslinks 2015

At this years Cancer Crosslinks we made short video interviews with presenters Professor Paul Baas, Professor Nicholas Navin, Professor Bjørn Tore Gjertsen and Professor Kimmo Porkka on their research and views on cancer treatments in the future. You may watch them below.

We would like to thank the presenters for taking the time to share their knowledge and our sponsors Bristol-Myers Squibb and Roche for making it possible to produce these videos.